Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Pathogenesis of and risk factors for cardiac allograft vasculopathy

Howard J Eisen, MD
Section Editor
Sharon A Hunt, MD
Deputy Editor
Susan B Yeon, MD, JD, FACC


Cardiac transplantation is the definitive therapy for eligible patients with end-stage heart failure. The major limitations to survival in the early post-transplant period (first year) are nonspecific graft failure, multiorgan failure, acute rejection, and infection [1]. Beyond the first year, cardiac allograft vasculopathy (CAV, also called transplant coronary artery disease or cardiac transplant vasculopathy) is among the top three causes of death [1]. Approximately 30 percent of patients have angiographic coronary artery disease at five years and 50 percent at 10 years, with the incidence increasing progressively with time [1]. (See "Prognosis after cardiac transplantation", section on 'Causes of death' and "Diagnosis and prognosis of cardiac allograft vasculopathy".)

The pathogenesis of CAV will be reviewed here. The diagnosis, prevention, and treatment of this disease are discussed separately. (See "Prevention and treatment of cardiac allograft vasculopathy" and "Diagnosis and prognosis of cardiac allograft vasculopathy".)


Cardiac allograft vasculopathy (CAV) is a panarterial disease confined to the allograft and is characterized by diffuse concentric longitudinal intimal hyperplasia in the epicardial coronary arteries (figure 1) [2-4] and concentric medial disease in the microvasculature [5-7]. In contrast, traditional atherosclerosis is focal, noncircumferential, and most often observed proximally in the epicardial vessels.

Transplant recipients also frequently develop proximal coronary artery disease. However, these lesions more closely resemble traditional atherosclerosis pathologically and probably evolve from pre-existing disease in the donor heart that is accelerated by the plethora of cardiac risk factors after transplantation [4].

Serial intravascular (intracoronary) ultrasound testing has shown that most of the intimal thickening occurs during the first year after transplantation [8]. Lumen loss is also due to arterial remodeling, with early expansion and late constriction of the external elastic membrane area. (See "Diagnosis and prognosis of cardiac allograft vasculopathy", section on 'Epidemiology'.)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Dec 21, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Lund LH, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report--2014; focus theme: retransplantation. J Heart Lung Transplant 2014; 33:996.
  2. Uretsky BF, Murali S, Reddy PS, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987; 76:827.
  3. Pollack MS, Ballantyne CM. HLA match and other immunologic parameters in relation to survival, rejection severity and accelerated coronary artery disease after heart transplant. Clin Transplant 1990; 4:269.
  4. Tuzcu EM, De Franco AC, Goormastic M, et al. Dichotomous pattern of coronary atherosclerosis 1 to 9 years after transplantation: insights from systematic intravascular ultrasound imaging. J Am Coll Cardiol 1996; 27:839.
  5. Billingham ME. Graft coronary disease: the lesions and the patients. Transplant Proc 1989; 21:3665.
  6. Tanaka H, Swanson SJ, Sukhova G, et al. Early proliferation of medial smooth muscle cells in coronary arteries of rabbit cardiac allografts during immunosuppression with cyclosporine A. Transplant Proc 1995; 27:2062.
  7. Hiemann NE, Wellnhofer E, Knosalla C, et al. Prognostic impact of microvasculopathy on survival after heart transplantation: evidence from 9713 endomyocardial biopsies. Circulation 2007; 116:1274.
  8. Tsutsui H, Ziada KM, Schoenhagen P, et al. Lumen loss in transplant coronary artery disease is a biphasic process involving early intimal thickening and late constrictive remodeling: results from a 5-year serial intravascular ultrasound study. Circulation 2001; 104:653.
  9. Mehra MR, Ventura HO, Jain SP, et al. Heterogeneity of cardiac allograft vasculopathy: clinical insights from coronary angioscopy. J Am Coll Cardiol 1997; 29:1339.
  10. Arbustini E, Dal Bello B, Morbini P, et al. Frequency and characteristics of coronary thrombosis in the epicardial coronary arteries after cardiac transplantation. Am J Cardiol 1996; 78:795.
  11. Arbustini E, Dal Bello B, Morbini P, et al. Immunohistochemical characterization of coronary thrombi in allograft vascular disease. Transplantation 2000; 69:1095.
  12. Fateh-Moghadam S, Bocksch W, Ruf A, et al. Changes in surface expression of platelet membrane glycoproteins and progression of heart transplant vasculopathy. Circulation 2000; 102:890.
  13. Hillebrands JL, Klatter FA, van den Hurk BM, et al. Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in transplant arteriosclerosis. J Clin Invest 2001; 107:1411.
  14. Eisenberg MS, Chen HJ, Warshofsky MK, et al. Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 2000; 102:2100.
  15. Labarrere CA, Lee JB, Nelson DR, et al. C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet 2002; 360:1462.
  16. Hognestad A, Endresen K, Wergeland R, et al. Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. J Am Coll Cardiol 2003; 42:477.
  17. Kaczmarek I, Deutsch MA, Kauke T, et al. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant 2008; 6:229.
  18. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report--2007. J Heart Lung Transplant 2007; 26:769.
  19. Narrod J, Kormos R, Armitage J, et al. Acute rejection and coronary artery disease in long-term survivors of heart transplantation. J Heart Transplant 1989; 8:418.
  20. Radovancevic B, Birovljev S, Vega JD, et al. Inverse relationship between human leukocyte antigen match and development of coronary artery disease. Transplant Proc 1991; 23:1144.
  21. Tambur AR, Pamboukian SV, Costanzo MR, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 2005; 80:1019.
  22. Radovancevic B, Poindexter S, Birovljev S, et al. Risk factors for development of accelerated coronary artery disease in cardiac transplant recipients. Eur J Cardiothorac Surg 1990; 4:309.
  23. Zerbe T, Uretsky B, Kormos R, et al. Graft atherosclerosis: effects of cellular rejection and human lymphocyte antigen. J Heart Lung Transplant 1992; 11:S104.
  24. Lindelöw B, Bergh C, Lamm C, et al. Graft coronary artery disease is strongly related to the aetiology of heart failure and cellular rejections. Eur Heart J 1999; 20:1326.
  25. Stoica SC, Cafferty F, Pauriah M, et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant 2006; 25:420.
  26. Raichlin E, Edwards BS, Kremers WK, et al. Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation. J Heart Lung Transplant 2009; 28:320.
  27. Schmid C, Heemann U, Tilney NL. Factors contributing to the development of chronic rejection in heterotopic rat heart transplantation. Transplantation 1997; 64:222.
  28. Tuzcu EM, Kapadia SR, Sachar R, et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2005; 45:1538.
  29. Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25:153.
  30. Suciu-Foca N, Reed E, Marboe C, et al. The role of anti-HLA antibodies in heart transplantation. Transplantation 1991; 51:716.
  31. Petrossian GA, Nichols AB, Marboe CC, et al. Relation between survival and development of coronary artery disease and anti-HLA antibodies after cardiac transplantation. Circulation 1989; 80:III122.
  32. Cherry R, Nielsen H, Reed E, et al. Vascular (humoral) rejection in human cardiac allograft biopsies: relation to circulating anti-HLA antibodies. J Heart Lung Transplant 1992; 11:24.
  33. Dunn MJ, Crisp SJ, Rose ML, et al. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet 1992; 339:1566.
  34. Fredrich R, Toyoda M, Czer LS, et al. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation 1999; 67:385.
  35. Taylor DO, Yowell RL, Kfoury AG, et al. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 2000; 19:518.
  36. Hruban RH, Beschorner WE, Baumgartner WA, et al. Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis. Am J Pathol 1990; 137:871.
  37. Salomon RN, Hughes CC, Schoen FJ, et al. Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol 1991; 138:791.
  38. Nielsen H, Symmans F, Marboe CC, et al.. Arteriopathy in human cardiac allografts: An immunopathologic study: Cell phenotyping and expression of adhesions molecules. Am J Pathol (in press).
  39. Marboe CC, Schierman SW, Rose E, et al. Characterization of mononuclear cell infiltrates in human cardiac allografts. Transplant Proc 1984; 16:1598.
  40. Doherty PC, Allan JE, Lynch F, Ceredig R. Dissection of an inflammatory process induced by CD8+ T cells. Immunol Today 1990; 11:55.
  41. Chomette G, Auriol M, Delcourt A, et al. Human cardiac transplants. Diagnosis of rejection by endomyocardial biopsy. Causes of death (about 30 autopsies). Virchows Arch A Pathol Anat Histopathol 1985; 407:295.
  42. Briscoe DM, Schoen FJ, Rice GE, et al. Induced expression of endothelial-leukocyte adhesion molecules in human cardiac allografts. Transplantation 1991; 51:537.
  43. Tanio JW, Basu CB, Albelda SM, Eisen HJ. Differential expression of the cell adhesion molecules ICAM-1, VCAM-1, and E-selectin in normal and posttransplantation myocardium. Cell adhesion molecule expression in human cardiac allografts. Circulation 1994; 89:1760.
  44. Koskinen PK, Lemström KB. Adhesion molecule P-selectin and vascular cell adhesion molecule-1 in enhanced heart allograft arteriosclerosis in the rat. Circulation 1997; 95:191.
  45. Labarrere CA, Nelson DR, Faulk WP. Endothelial activation and development of coronary artery disease in transplanted human hearts. JAMA 1997; 278:1169.
  46. Labarrere CA, Nelson DR, Miller SJ, et al. Value of serum-soluble intercellular adhesion molecule-1 for the noninvasive risk assessment of transplant coronary artery disease, posttransplant ischemic events, and cardiac graft failure. Circulation 2000; 102:1549.
  47. Bayliss J, Bailey M, Leet A, et al. Late onset antibody-mediated rejection and endothelial localization of vascular endothelial growth factor are associated with development of cardiac allograft vasculopathy. Transplantation 2008; 86:991.
  48. Kübrich M, Petrakopoulou P, Kofler S, et al. Impact of coronary endothelial dysfunction on adverse long-term outcome after heart transplantation. Transplantation 2008; 85:1580.
  49. Libby P, Warner SJ, Friedman GB. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 1988; 81:487.
  50. Raines EW, Dower SK, Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 1989; 243:393.
  51. Fellström B, Dimeny E, Larsson E, et al. Importance of PDGF receptor expression in accelerated atherosclerosis-chronic rejection. Transplant Proc 1989; 21:3689.
  52. Lou H, Zhao Y, Delafontaine P, et al. Estrogen effects on insulin-like growth factor-I (IGF-I)-induced cell proliferation and IGF-I expression in native and allograft vessels. Circulation 1997; 96:927.
  53. Gullestad L, Simonsen S, Ueland T, et al. Possible role of proinflammatory cytokines in heart allograft coronary artery disease. Am J Cardiol 1999; 84:999.
  54. Miller GG, Davis SF, Atkinson JB, et al. Longitudinal analysis of fibroblast growth factor expression after transplantation and association with severity of cardiac allograft vasculopathy. Circulation 1999; 100:2396.
  55. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331:1286.
  56. Densem CG, Hutchinson IV, Cooper A, et al. Polymorphism of the transforming growth factor-beta 1 gene correlates with the development of coronary vasculopathy following cardiac transplantation. J Heart Lung Transplant 2000; 19:551.
  57. Nagano H, Mitchell RN, Taylor MK, et al. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 1997; 100:550.
  58. Ternstrom L, Jeppsson A, Ricksten A, Nilsson F. Tumor necrosis factor gene polymorphism and cardiac allograft vasculopathy. J Heart Lung Transplant 2005; 24:433.
  59. Densem CG, Ray M, Hutchinson IV, et al. Interleukin-6 polymorphism: a genetic risk factor for cardiac transplant related coronary vasculopathy? J Heart Lung Transplant 2005; 24:559.
  60. Gao HZ, Hunt SA, Alderman EL, et al. Relation of donor age and preexisting coronary artery disease on angiography and intracoronary ultrasound to later development of accelerated allograft coronary artery disease. J Am Coll Cardiol 1997; 29:623.
  61. Bolad IA, Robinson DR, Webb C, et al. Impaired left ventricular systolic function early after heart transplantation is associated with cardiac allograft vasculopathy. Am J Transplant 2006; 6:161.
  62. Johnson MR. Transplant coronary disease: nonimmunologic risk factors. J Heart Lung Transplant 1992; 11:S124.
  63. Hosenpud JD, Shipley GD, Wagner CR. Cardiac allograft vasculopathy: current concepts, recent developments, and future directions. J Heart Lung Transplant 1992; 11:9.
  64. Chang G, DeNofrio D, Desai S, et al. Lipoprotein(a) levels and heart transplantation atherosclerosis. Am Heart J 1998; 136:329.
  65. DeNofrio D, Desai S, Rader DJ, et al. Changes in lipoprotein(a) concentration after orthotopic heart transplantation. Am Heart J 2000; 139:729.
  66. Escobar A, Ventura HO, Stapleton DD, et al. Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol 1994; 74:1042.
  67. Kapadia SR, Nissen SE, Ziada KM, et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study. J Am Coll Cardiol 2001; 38:206.
  68. Holvoet P, Van Cleemput J, Collen D, Vanhaecke J. Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 2000; 20:698.
  69. Shi C, Lee WS, Russell ME, et al. Hypercholesterolemia exacerbates transplant arteriosclerosis via increased neointimal smooth muscle cell accumulation: studies in apolipoprotein E knockout mice. Circulation 1997; 96:2722.
  70. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333:621.
  71. Fateh-Moghadam S, Bocksch W, Wessely R, et al. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation 2003; 76:1470.
  72. Bonaros NE, Kocher A, Dunkler D, et al. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. Transplantation 2004; 77:890.
  73. Potena L, Grigioni F, Ortolani P, et al. Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. Transplantation 2003; 75:839.
  74. Sedmak DD, Roberts WH, Stephens RE, et al. Inability of cytomegalovirus infection of cultured endothelial cells to induce HLA class II antigen expression. Transplantation 1990; 49:458.
  75. Kato T, Chan MC, Gao SZ, et al. Glucose intolerance, as reflected by hemoglobin A1c level, is associated with the incidence and severity of transplant coronary artery disease. J Am Coll Cardiol 2004; 43:1034.
  76. Valantine H, Rickenbacker P, Kemna M, et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Circulation 2001; 103:2144.
  77. Biadi O, Potena L, Fearon WF, et al. Interplay between systemic inflammation and markers of insulin resistance in cardiovascular prognosis after heart transplantation. J Heart Lung Transplant 2007; 26:324.
  78. Moons L, Shi C, Ploplis V, et al. Reduced transplant arteriosclerosis in plasminogen-deficient mice. J Clin Invest 1998; 102:1788.
  79. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. N Engl J Med 1995; 333:1111.
  80. Dawson S, Hamsten A, Wiman B, et al. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11:183.
  81. Benza RL, Grenett HE, Bourge RC, et al. Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease. Circulation 1998; 98:2248.
  82. Labarrere CA, Torry RJ, Nelson DR, et al. Vascular antithrombin and clinical outcome in heart transplant patients. Am J Cardiol 2001; 87:425.
  83. Fish RD, Nabel EG, Selwyn AP, et al. Responses of coronary arteries of cardiac transplant patients to acetylcholine. J Clin Invest 1988; 81:21.
  84. Davis SF, Yeung AC, Meredith IT, et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation 1996; 93:457.
  85. Hollenberg SM, Klein LW, Parrillo JE, et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 2001; 104:3091.
  86. Hollenberg SM, Klein LW, Parrillo JE, et al. Changes in coronary endothelial function predict progression of allograft vasculopathy after heart transplantation. J Heart Lung Transplant 2004; 23:265.
  87. Koglin J, Glysing-Jensen T, Mudgett JS, Russell ME. Exacerbated transplant arteriosclerosis in inducible nitric oxide-deficient mice. Circulation 1998; 97:2059.
  88. Iwata A, Sai S, Moore M, et al. Gene therapy of transplant arteriopathy by liposome-mediated transfection of endothelial nitric oxide synthase. J Heart Lung Transplant 2000; 19:1017.
  89. Tanaka M, Sydow K, Gunawan F, et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 2005; 112:1549.
  90. Ravalli S, Albala A, Ming M, et al. Inducible nitric oxide synthase expression in smooth muscle cells and macrophages of human transplant coronary artery disease. Circulation 1998; 97:2338.
  91. De Souza AI, Wait R, Mitchell AG, et al. Heat shock protein 27 is associated with freedom from graft vasculopathy after human cardiac transplantation. Circ Res 2005; 97:192.
  92. Cunningham DA, Crisp SJ, Barbir M, et al. Donor ACE gene polymorphism: a genetic risk factor for accelerated coronary sclerosis following cardiac transplantation. Eur Heart J 1998; 19:319.
  93. Richter M, Skupin M, Grabs R, et al. New approach in the therapy of chronic rejection? ACE- and AT1-blocker reduce the development of chronic rejection after cardiac transplantation in a rat model. J Heart Lung Transplant 2000; 19:1047.
  94. Bobik A, Grooms A, Millar JA, et al. Growth factor activity of endothelin on vascular smooth muscle. Am J Physiol 1990; 258:C408.
  95. Ravalli S, Szabolcs M, Albala A, et al. Increased immunoreactive endothelin-1 in human transplant coronary artery disease. Circulation 1996; 94:2096.
  96. Okada K, Nishida Y, Murakami H, et al. Role of endogenous endothelin in the development of graft arteriosclerosis in rat cardiac allografts: antiproliferative effects of bosentan, a nonselective endothelin receptor antagonist. Circulation 1998; 97:2346.
  97. Lim TT, Liang DH, Botas J, et al. Role of compensatory enlargement and shrinkage in transplant coronary artery disease. Serial intravascular ultrasound study. Circulation 1997; 95:855.
  98. Kobashigawa J, Wener L, Johnson J, et al. Longitudinal study of vascular remodeling in coronary arteries after heart transplantation. J Heart Lung Transplant 2000; 19:546.
  99. Wong C, Ganz P, Miller L, et al. Role of vascular remodeling in the pathogenesis of early transplant coronary artery disease: a multicenter prospective intravascular ultrasound study. J Heart Lung Transplant 2001; 20:385.
  100. Mehra MR, Uber PA, Ventura HO, et al. The impact of mode of donor brain death on cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol 2004; 43:806.
  101. Yamani MH, Starling RC, Cook DJ, et al. Donor spontaneous intracerebral hemorrhage is associated with systemic activation of matrix metalloproteinase-2 and matrix metalloproteinase-9 and subsequent development of coronary vasculopathy in the heart transplant recipient. Circulation 2003; 108:1724.
  102. Yamani MH, Haji SA, Starling RC, et al. Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. J Am Coll Cardiol 2002; 39:970.
  103. Cowan B, Baron O, Crack J, et al. Elafin, a serine elastase inhibitor, attenuates post-cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits afer heterotopic cardiac transplantation. J Clin Invest 1996; 97:2452.
  104. Zhao XM, Hu Y, Miller GG, et al. Association of thrombospondin-1 and cardiac allograft vasculopathy in human cardiac allografts. Circulation 2001; 103:525.
  105. Yamani MH, Masri CS, Ratliff NB, et al. The role of vitronectin receptor (alphavbeta3) and tissue factor in the pathogenesis of transplant coronary vasculopathy. J Am Coll Cardiol 2002; 39:804.
  106. Haji SA, Starling RC, Avery RK, et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant 2004; 23:277.
  107. Miriuka SG, Delgado DH, Cole DE, et al. Hyperhomocysteinemia in heart transplantation: from bench to bedside. J Heart Lung Transplant 2003; 22:1069.
  108. Kutschka I, Pethig K, Harringer W, et al. Increased plasma homocysteine concentrations accelerate cardiac allograft vasculopathy. J Heart Lung Transplant 2004; 23:1260.
  109. Atkinson C, Southwood M, Pitman R, et al. Angiogenesis occurs within the intimal proliferation that characterizes transplant coronary artery vasculopathy. J Heart Lung Transplant 2005; 24:551.
  110. Martínez-Dolz L, Almenar L, Reganon E, et al. Follow-up study on the utility of von Willebrand factor levels in the diagnosis of cardiac allograft vasculopathy. J Heart Lung Transplant 2008; 27:760.